

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: BM2/22 - Bone Markers

Deadline: 28.10.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}
(431) Parathyrin intact (PTH)					27						26	23	88%
Samples and groups	[pmol/L]												
Sample A		8,16	2,8	34	27						26	24	92%
(60) Roche		6,93	1,0	15	16	0	CVPG	6,89	0,25	23%	5,3	8,48	16
(179) Siemens		8,10	0,29	3,6	5	0	CVPG	8,22	0,34	23%	6,32	10,2	5
Other					6	1							5
								4x 1, 1x 12, 1x 29					
Sample B		21,2	6,3	30	27						26	23	88%
(60) Roche		19,1	3,2	17	16	0	CVPG	20	0,78	23%	15,4	24,6	16
(179) Siemens		24,4	0,50	2,1	5	0	CVPG	25	0,92	23%	19,2	30,8	5
Other					6	0							5
								4x 1, 1x 12, 1x 29					
(432) Collagen telopeptide CTx-beta					21						21	18	86%
Samples and groups	[ng/L]												
Sample A		304	29	9,7	21						21	19	90%
(60) Roche		304	29	9,7	21	0	CVPG	299	5,4	17%	248	350	21
Sample B		707	80	11	21						21	18	86%
(60) Roche		707	80	11	21	0	CVPG	711	14	17%	590	832	21
(433) P1NP					14						14	11	79%
Samples and groups	[µg/L]												
Sample A		34,3	3,4	9,8	14						14	11	79%
(60) Roche		34,3	3,4	9,8	14	0	CVPG	33,4	0,85	20%	26,7	40,1	14
Sample B		199	33	16	14						14	11	79%
(60) Roche		199	33	16	14	0	CVPG	213	5,7	20%	170	256	14
(434) Osteocalcin					19						18	15	83%
Samples and groups	[µg/L]												
Sample A		18,2	1,3	7,0	19						18	16	89%
(60) Roche		18,3	1,1	6,3	18	0	CVPG	18,5	0,31	13%	16	21	18
Other					1	0							0
								1x 164					
Sample B		85,5	9,2	11	19						18	15	83%
(60) Roche		86,6	7,9	9,1	18	0	CVPG	91,1	1,8	13%	79,2	103	18
Other					1	0							0
								1x 164					
(435) 25-hydroxyvitamin D					29						28	24	86%
Samples and groups	[nmol/L]												
Sample A		72,8	18	24	29						28	25	89%
(60) Roche		72,7	15	20	21	0	CVPG	71,4	3,5	33%	47,8	95	21
Other					8	0							7
								4x 1, 1x 12, 2x 179, 1x 998					
Sample B		156	32	20	29						28	24	86%
(60) Roche		154	25	16	21	0	CVPG	156	5,6	33%	104	208	21
Other					8	0							7
								4x 1, 1x 12, 2x 179, 1x 998					

st_kn_p

End of report

Printed: 07.11.2022